Publié le
Abstract: Purpose Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts…
Publié le
Randomized controlled trials (RCTs), particularly in phase 3, are the preferred sources of evidence for drug approval and reimbursement decisions….
Publié le
Join IDDI experts to get updated on efficacy assessment in early-phase trials and more! THURSDAY, FEBRUARY 3 – 9:00 –…
Publié le
Be updated on different types of Bayesian and frequentist designs that may be used for expansion cohorts in phase 1…
Publié le
This webinar was presented by Laurence Collette, MSc, PhD, Principal Statistician, Consulting Services at IDDI at the 5th Annual Next…
Publié le
Demystifying different types of Bayesian and frequentist designs that may be used for first-in-human or other types of phase I…
Publié le
With some of the recently developed drugs showing unprecedented response rates and consistent improvement in overall survival in some indications,…
Publié le
WATCH RECORDED WEBINAR Drug development in oncology is undergoing several changes brought about by precision medicine, which makes it appealing…
Publié le
Nowadays, drug development in oncology is largely centered on the basic premise of precision medicine, according to which targeted agents…
Publié le
Estimands Framework: Ensuring alignment between the key scientific question of interest, analysis and interpretation during clinical trial design. The estimands…
